| Objective:to analyze the safety and efficacy of tirofiban on acute ischemic stroke,provide basis for clinical treatment and provide theoretical basis for large-scale randomized controlled trials in the future.Methods:By searching Pub Med,Embase,The Cochrane Library,Web of Science and other databases,randomized controlled trials and prospective cohort studies that met the inclusion and exclusion criteria were selected.the retrieval time was from establishment time of the database to March 18,2022.Two evaluators independently evaluated the quality of the included study,extracted data and cross-checked,and the homogeneous study was analyzed by Rev Man5.3 software Meta.Results:A total of 16 studies were included,including 4700 patients.Meta analysis showed that the safety of tirofiban in the treatment of acute ischemic stroke did not increase the incidence of intracranial hemorrhage,symptomatic hemorrhage transformation and fatal hemorrhage transformation,which were [OR=0.86,95%CI(0.72,1.02),P=0.09]、[OR=1.02,95%CI(0.81,1.29),P=0.85]、[OR=1.61,95%CI(0.81,3.20),P=0.17].And it can reduce the incidence of death [OR=0.71,95%CI(0.60,0.85),P=0.0001].The 90-day prognosis of tirofiban combined with tirofiban was better than that of the control group[OR=1.16,95%CI(1.02,1.32),P=0.02],but there was no significant difference in the incidence of recanalization between the two groups [OR=1.17,95%CI(0.79,1.72),P=0.44],and the incidence of reocclusion was not significantly different from that of the control group[OR=1.09,95%CI(0.56,2.09),P=0.81].Conclusion:1.The use of tirofiban will not increase the incidence of intracranial hemorrhage,symptomatic hemorrhage transformation and fatal hemorrhage transformation in patients with acute ischemic stroke,but can significantly reduce the mortality.2.Tirofiban seems to improve the long-term prognosis of patients with acute ischemic stroke,but it does not seem to improve the incidence of recanalization or reduce the incidence of reocclusion. |
PDF Full Text Request